Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: A theranostic potential for PPP cardiology

EPMA Journal

Volumn 4, Issue 1, 2013, Pages

  Spivak, Mykola Ya ^a,b   Bubnov, Rostyslav V ^a,c   Yemets, Ilya M ^d   Lazarenko, Liudmyla M ^a   Tymoshok, Natalia O ^a   Ulberg, Zoia R ^e  

^a ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^b LCL DIAPROF   (Ukraine)

^c Clinical Hospital Pheophania of State Affairs Department   (Ukraine)

^d Cardiac Health of Ukraine   (Ukraine)

^e INSTITUTE OF BIOCOLLOID CHEMISTRY   (Ukraine)

Author keywords

Animal model; Drug delivery; Gold nanoparticles; Heart failure; Nanomedicine; Personalized medicine; Predictive; Preventive; Sonoporation; Theranostics

Indexed keywords

DOXORUBICIN; GOLD NANOPARTICLE; LEVOSIMENDAN; NANOCARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BIOCOMPATIBILITY; BIOSAFETY; CARDIAC MUSCLE CELL; CARDIOLOGY; CONTROLLED STUDY; DISEASE COURSE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; ECHOCARDIOGRAPHY; GENOTOXICITY; HEART FAILURE; HEART PROTECTION; HEPATOMEGALY; HYDROTHORAX; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRION; NONHUMAN; PARTICLE SIZE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RAT; SONOPORATION EFFECT; THERANOSTIC NANOMEDICINE; WISTAR RAT;

EID: 85049381439     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-4-20     Document Type: Article

References (90)

1. Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J 2012, 3:14.
2. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M: Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002, 87(3):235–241.
3. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK: Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002, 23(23):1867–1876.
4. Neubauer S: The failing heart — an engine out of fuel. N Engl J Med 2007, 356(11):1140–1151.
5. National Research Council: Guide for the Care and Use of Laboratory Animals. Eighth edition. Washington: The National Academies; 2011:246.
6. Doggrell SA, Brown L: Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998, 39(1):89–105.
7. Kannel WB: Hypertension as a risk for cardiac events – epidemiological results of long-term studies. J Cardiovasc Pharmacol 1993, 21(Suppl 2):S27–S37.
8. Bubnov RV, Spivak MY, Zholobak NM: Method for experimental modeling of biological processes. Patent Ukraine 2013, 78:082.
9. IPC A61B 10/00 A61B 8/00 A61D 99/00, issued. 11.03.2013 (Bull. N 5).
10. Colin KL, Turnbull DH: Ultrasound biomicroscopy-Doppler in mouse cardiovascular development. Physiol Genomics 2003, 14:3–15.
11. Kiessling F, Pichler Bernd J: Small Animal Imaging: Basics and Practical Guide. 1st edition. Heidelberg: Springer; 2011.
12. Bubnov RV, Spivak MY, Zholobak NM: The use the ultrasound equipment of general use for in vivo study of cerium dioxide nanoparticles introduction in mice. In Proceedings of scientific conference with international participation on Innovative Technologies in Ultrasonic Diagnosis. Kyiv: Pheophania; 2011:25–28.
13. Bubnov RV: The use of ultrasound equipment of general use for in vivo study of cerium dioxide nanoparticles introduction in mice. Ultrasound Med Biol 2011, 37(8):1–S162. doi:10.1016/j.ultrasmedbio.2011.05.750.
14. Spivak MY, Yemets IM, Bubnov RV: Method modeling of heart failure. Patent Ukraine 2013, 78: 105. IPC A61B 10/00 A61B 8/00, issued. 11.03.2013 (Bull. N 5).
15. Bjornerheim R, Kiil Grogaard H, Kjekshus H, Attramadal H, Smiseth OA: High frame rate doppler echocardiography in the rat: an evaluation of the method. Eur J Echocardiogr 2001, 2:78–87.
16. Holinski S, Knebel F, Heinze G, Konertz W, Baumann G, Borges AC: Noninvasive monitoring of cardiac function in a chronic ischemic heart failure model in the rat: assessment with tissue Doppler and non- Doppler 2D strain echocardiography. Cardiovasc Ultrasound 2011, 26(9):15.
17. Pollick C, Hale SL, Kloner RA: Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 1995, 8(5 Pt 1):602–610.
18. Lu L, Ko E, Schwartz GG, Chou TM: Transesophageal echocardiography in rats using an intravascular ultrasound catheter. Am J Physiol 1997, 273(4 Pt 2):H2078–H2082.
19. Cingolani OH, Yang XP, Cavasin MA, Carretero OA: Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 2003, 41:249–254.
20. Sjaastad I, Sejersted OM, Ilebekk A, Bjørnerheim R: Echocardiographic criteria for detection of post infarction congestive heart failure in rats. J Appl Physiol 2000, 89:1445–1454.
21. Saraiva RM, Kanashiro-Takeuchi RM, Antonio EL, Campos OPJFT, Moisés VA: Rats with high left ventricular end-diastolic pressure can be identified by Doppler echocardiography one week after myocardial infarction. Braz J Med Biol Res 2007, 40(11):1557–1565.
22. Kokubo M, Uemura A, Matsubara T, Murohara T: Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens Res 2005, 28(7):601–609.
23. de Simone G, Wallerson DC, Volpe M, Devereux RB: Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation Am J Hypertens 1990, 3:688–696.
24. Martinez PF, Okoshi K, Zornoff LA, Oliveira SA Jr, Campos DH, Lima AR, Damatto RL, Cezar MD, Bonomo C, Guizoni DM, Padovani CR, Cicogna AC, Okoshi MP: Echocardiographic detection of congestive heart failure in postinfarction rats. J Appl Physiol 2011, 111(2):543–551.
25. Miller DL: Induction of pulmonary hemorrhage in rats during diagnostic ultrasound. Ultrasound Med Biol 2012, 38(8):1476–1482.
26. Lee RM, Triggle CR, Cheung DW, Coughlin MD: Structural and functional consequence of neonatal sympathectomy on the blood vessels of spontaneously hypertensive rats. Hypertension 1987, 10:328–338.
27. Hayward R, Hydock DS: Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci 2007, 46(4):20–32.
28. Kharin S, Krandycheva V, Tsvetkova A, Strelkova M, Shmakov D: Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model. Fundam Clin Pharmacol 2012, 27(4):364–372.
29. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900–905.
30. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R: Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics 1992, 89:942–949.
31. Dimitrakis P, Romay-Ogando MI, Timolati F, Suter TM, Zuppinger C: Effects of doxorubicin cancer therapy on autophagy and the ubiquitinproteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res 2012, 350(2):361–372.
32. Al Shabanah OA, Aleisa AM, Hafez MM, Al Rejaie SS, Al Yahya AA, Bakheet SA, Al Harbi MM, Sayed Ahmed MM: Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model. Oxid Med Cell Longev 2012, 2012:619185.
33. Fukuo Y, Nakatani T, Shinohara H, Matsuda T: The mouse pericardium: it allows passage of particulate matter from the pleural to the pericardial cavity. Anat Rec 1988, 222(1):1–5.
34. Nakatani T, Shinohara H, Fukuo Y, Morisawa S, Matsuda T: Pericardium of rodents: pores connect the pericardial and pleural cavities. Anat Rec 1988, 220(2):132–137.
35. Spivak M, Bubnov R, Yemets I, Lazarenko L, Timoshok N, Vorobieva A, Mohnatyy S, Ulberg Z, Reznichenko L, Grusina T, Zhovnir V, Zholobak N: Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats. longitudinal in vivo study. Med Ultrason 2013, 15(1):23–28.
36. Trikas A, Antoniades C, Latsios G, Vasiliadou K, Karamitros I, Tousoulis D, Tentolouris C, Stefanadis C: Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006, 8(8):804–809.
37. Rieznichenko LS, Dybkova SM, Gruzina TG, Ulberg ZR, Todor IN, Lukyanova NY, Shpyleva SI: Chekhun VF:Gold nanoparticles synthesis and biological activity estimation in vitro and in vivo. Exp Oncol 2012, 34(1):25–28.
38. Kogan MJ, Bastus NG, Amigo R, Grillo-Bosch D, Araya E, Turiel A, Labarta A, Giralt E, Puntes VF: Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett 2006, 6(1):110–115.
39. Boisselier E, Astruc D: Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38:1759–1782.
40. Shukla R, Chanda N, Zambre A, Upendran A, Katti K, Kulkarni RR, Nune SK, Casteel SW, Smith CJ, Vimal J, Boote E, Robertson JD, Kan P, Engelbrecht H, Watkinson LD, Carmack TL, Lever JR, Cutler CS, Caldwell C, Kannan R, Katti KV: Laminin receptor specific therapeutic gold nanoparticles (198AuNPEGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci USA 2012, 31(31):109. 12426–31.
41. Link S, El-Sayed MA: Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver nanodots and nanorods. J Phys Chem B 1999, 103(40):8410–8426.
42. Link S, El-Sayed MA: Shape and size dependence of radiative, nonradiative and photothermal properties of gold nanocrystals. Int Rev Phys Chem 2000, 19(3):409–453.
43. Link S, El-Sayed MA: Optical properties and ultrafast dynamics of metallic nanocrystals. Annu Rev Phys Chem 2003, 54:331–366.
44. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Timoshok NO, Ulberg ZR: Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application. EPMA J 2013, 4:18.
45. Huang X, El-Sayed MA: Gold nanoparticles optical properties and implementations in cancer diagnosis and photothermal therapy. J Ad Res 2010, 1:13–28.
46. Thompson DT: Using gold nanoparticles for catalysis. Nano Today 2007, 2:40–43.
47. Sperling RA, Gil PRF, Zhang M: Zanella biological applications of gold nanoparticles Chem. Soc Rev 2008, 37:1896–1908.
48. Haes AJ, Hall WP, Chang L, Klein WL, Van Duyne RP: A localized surface plasmon resonance biosensor: first steps toward an Alzheimer's disease. Assa Nano Lett 2004, 4:1029–1034.
49. Haes AJ, Chang L, Klein WL, Van Duyne RP: Detection of a biomarker for Alzheimer’s disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 2005, 127:2264–2271.
50. Bowman M-C, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C: Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 2008, 130:6896–6897.
51. Xi D, Luo X, Ning Q, Lu Q, Yao K, Liu Z: The detection of HBV DNA with gold nanoparticle gene probes. J Nanjing Med Univ 2007, 21(4):207–212.
52. Baptista PV, Koziol-Montewka M, Paluch-Oles J, Doria G, Franco R: Goldnanoparticle- probe–based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clin Chem 2006, 52:1433–1434.
53. Baptista P, Pereira E, Eaton P, Doria G, Miranda A, Gomes I, Quaresma P, Franco R: Gold nanoparticles for the development of clinical diagnosis methods. Anal Bioanal Chem 2008, 391(3):943–950.
54. Coelho J, Ferreira P, Alves P, Cordeiro R, Fonseca A, Góis J, Gil M: Drug delivery systems: advanced technologies potentially applicable in personalized treatments. EPMA J 2010, 1:164–209.
55. Xu PS, Van EA, Kirk YH, Zhan WJ, Murdoch M, Radosz YQ: Shen targeted charge-reversal nanoparticles for nuclear drug delivery Angew. Chem Int 2007, 46:4999–5002.
56. Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka L: Acid- and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system. Biomacromolecules 2004, 5:524–529.
57. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A: Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int 2005, 44:6358–6362.
58. Salem AK, Searson PC, Leong KW: Multifunctional nanorods for gene delivery. Nat Mater 2003, 2:668–671.
59. Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ: Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 2010, 132:4678–4684.
60. Ghosh P, Han G, De M, Kim CH, Rotello VM: Gold nanoparticles in delivery applications. Adv Drug Delivery Rev 2008, 60:1307–1315.
61. Chekman IS, Ulberg ZR, Gorchakova NO, Nebesna TY, Gruzina TG, Priskoka AO, Doroshenko AM, Simonov PV: The prospects of medical application of metal-based nanoparticles and nanomaterials. Lik Sprava 2011, 1–2:3–21.
62. Mo R, Lin S, Wang G, Wang Y, Wu EX: Preliminary in vitro study of ultrasound sonoporation cell labeling with superparamagnetic iron oxide particles for MRI cell tracking. In Conference Proceedings of IEEE Eng Med Biol Soc 2008, 2008:367–370.
63. Yu Hsin W, Ai Ho L, Jia Yu L, Cheng Ru L, Cheng Ham W, Tzu Min L, Churng Ren W, Pai Chi L: Enhanced delivery of gold nanoparticles by acoustic cavitation for photoacoustic imaging and photothermal therapy. San Francisco: SPIE Proceedings 8581, Photons Plus Ultrasound: Imaging and Sensing; 2013:858123.
64. Toporova OK, Irodov DM, Bubnov RV, Kholodkova OL, Gulko TP, Ruban TP, Morgunov PV, Kordium VA: Intrahepatic ultrasound-mediated gene delivery. J Hepatol 2013, 58:S119. doi:10.1016/S0168-8278(13)60283-4.
65. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, Lee S, Park JH, Park RW, Kim IS, Choi K, Kim SY, Park K, Kwon IC: Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring J. Control Release 2010, 146(2):219–227.
66. Mittler R: Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci 2002, 7(9):405–410.
67. Asada K, Takahashi M: Production and scavenging of active oxygen in photosynthesis. In Photoinhibition. Edited by Kyle DJ, Osmond CB, Arntzen CJ. Amsterdam: Elsevier; 1987:227–287.
68. Barath Mani Kanth S, Kalishwaralal K, Sriram M, Pandian SRK, Youn HS, Eom S, Gurunathan S: Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J Nanobiotechnol 2010, 8:16.
69. Alvaro M, Aprile C, Corma A, Ferrer B, Garcia H: Influence of radical initiators in gold catalysis: evidence supporting trapping of radicals derived from azobis(isobutyronitrile) by gold halides. J Catal 2006, 245:249–252.
70. Navalon S, Martin R, Alvaro M, Garcia H: Gold on diamond nanoparticles as a highly efficient Fenton catalyst. Angew Chem Int Ed Engl 2001, 2(45):8403–8407. 49.
71. Andrews RJ: Neuroprotection at the nanolevel – Part I: Introduction to nanoneurosurgery. Ann NY Acad Sci 2007, 1122:169–184.
72. Seaton A, Tran L, Aitken R, Donaldson K: Nanoparticles, human health hazard and regulation. J R Soc Interface 2010, 7:119–129.
73. Freese C, Uboldi C, Gibson MI, Unger RE, Weksler BB, Romero IA, Couraud PO, Kirkpatrick CJ: Uptake and cytotoxicity of citrate-coated gold nanospheres: Comparative studies on human endothelial and epithelial cells. Part Fibre Toxicol 2012, 9:23.
74. Roman'ko MIe, Rieznichenko LS, Hruzina TH, Dybkova SM, Ul'berh ZR, Ushkalov VO, Holovko AM: Influence of gold and silver nanoparticles on ATPase activity of native and rehydrated cells of Escherichia coli. Ukr Biokhim Zh 2009, 81(6):70– 76. Ukrainian.
75. Ulberg ZR, Gruzina TG, Rieznichenko LS, Dybkova SM: Biological systems at various levels of the organization and the gold nanoparticles. In Nanosciences, Nanobiology, nanopharmacology. Edited by Chekman IS, Ulberg ZR, Malanchuk VA. Kyiv: Polygraph Plus; 2012:327.
76. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M: Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 2005, 21:10644–10654.
77. Zhang Q, Hitchins VM, Schrand AM, Hussain SM, Goering PL: Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-inflammatory mediators. Nanotoxicology 2011, 5(3):284–295.
78. Bubnov RV: Evidence-based pain management: is the concept of integrative medicine applicable. EPMA J 2012, 3(1):13.
79. Bubnov R, Yevseenko V, Semeniv I: Ultrasound guided injections of Platelets Rich Plasma for muscle injury in professional athletes. Comparative study. Med Ultrason 2013, 15(2):101–105. doi:10.11152/ mu.2013.2066.152.rb1vy2.
80. Chnari E, Nikitczuk JS, Uhrich KE, Moghe PV: Nanoscale anionic macromolecules can inhibit cellular uptake of differentially oxidized LDL. Biomacromolecules 2006, 7:597–603.
81. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT: Controlled delivery of PDGFBB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2006, 116:237–248.
82. Davis ME, Hsieh PC, Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, Lee RT: Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA 2006, 103:8155–8160.
83. Sy JC, Davis ME: Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res 2010, 3(5):461–468.
84. Powrie F, Coffman RL: Cytokine regulation of T-cell function: potential for therapeutic intervention. Trends Pharmacol Sci 1993, 14(5):164–168.
85. Astry B, Harberts E, Moudgil KD: A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011, 31(12):927–940.
86. Mill JG, Stefanon I, dos Santos L, Baldo MP: Remodeling in the ischemic heart: the stepwise progression for heart failure. Braz J Med Biol Res September 2011, 44(9):890–898.
87. Bhattacharya R, Mukherjee P, Xiong Z, Atala A, Soker S, Mukhopadhyay D: Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells. Nano Lett 2004, 4:2479–2481.
88. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA: Gene regulation with polyvalent siRNA−nanoparticle conjugates. J Am Chem Soc 2009, 131(6):2072–2073.
89. Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA: Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug Chem 2010, 21(12):2250–2256.
90. Kisak ET, Coldren B, Evans CA, Boyer C, Zasadzinski JA: The vesosome—a multicompartment drug delivery vehicle. Curr Med Chem 2004, 11:199–219.